Scientific Sessions
Scientific Sessions
  • Program
  • #AHA24
  • Late-Breaking Science
  • Daily Coverage
  • Industry Highlights
  • Photo Gallery
  • Journeys
Topics
  • Late-Breaking Science
  • Daily Coverage
  • Industry Highlights
  • Photo Gallery
  • Journeys
Resources
  • Program
  • #AHA24
User Tools
  • Privacy Policy
  • Terms & Conditions
  • Accessibility Statement
Twitter X icon Facebook iconInstagram iconYouTube iconPinterest iconLinkedIn icon
Oct 24th, 2024

Today's Late-Breaking and Featured Science

Three Late-Breakers and three Featured Science presentations are on tap for today.


audience shot

Late-Breaking Science

LBS.06 | Building on the Four Pillars: Novel Trials of Medical Therapy for Heart Failure
8:-9:15 a.m. | Main Event I
Heart Failure and Cardiomyopathies

  • Myeloperoxidase Inhibition With Mitiperstat in Heart Failure With Preserved and Mildly Reduced Ejection Fraction: Primary Results From the ENDEAVOR Randomized Clinical Trial
  • Effects of Sacubitril-Valsartan on Prevention of Cardiotoxicity in High-Risk Patients Undergoing Anthracycline Chemotherapy: A Double-Blind Randomized Placebo-Controlled Clinical Trial: The SARAH Trial
  • Novel Bumetanide Nasal Spray (BNS) Demonstrates Safety, Tolerability and Equivalent Efficacy Compared to Intravenous and Oral Bumetanide (RSQ-777-02)
  • Sodium Zirconium Cyclosilicate and MRA Optimization in Heart Failure With Reduced Ejection Fraction and Hyperkalemia: Main Results From REALIZE-K Randomized Controlled Trial

LBS.07 | Revolutionizing AF Management: Cutting-Edge Approaches
9:45–11 a.m. | Main Event I
Electrophysiology and Arrhythmias

  • Comparison of Linear Ablation Plus Pulmonary Vein Isolation vs. Pulmonary Vein Isolation Alone for Persistent Atrial Fibrillation: Results From the PROMPT-AF Randomized Trial
  • Cryoballoon Ablation vs. Radiofrequency Ablation in Patients With Persistent Atrial Fibrillation (CRRF-PeAF): A Prospective, Multicenter, Randomized, Noninferiority Clinical Trial
  • Randomized Controlled Trial of Metformin and Lifestyle/Risk Factor Modification for Upstream Prevention of Atrial Fibrillation Progression: The Targeting Risk Interventions and Metformin for Atrial Fibrillation (TRIM-AF) Trial
  • Aggressive Risk Factor Reduction Study for Atrial Fibrillation (ARREST-AF) Implications for Ablation Outcomes: A Randomized Clinical Trial 

LBS.08 | New Targets and New Treatments: Advances in Lipid Therapeutics
1:30–2:45 p.m. | Main Event I
Prevention and Lifestyle Medicine

  • ALPACAR Phase 2 Trial of Zerlasiran: Multiple Doses of a Short-Interfering RNA Targeting Lipoprotein(a) Over 60 weeks.
  • A Randomized Phase 2 Trial of Muvalaplin: An Oral Disrupter of the Assembly of Lipoprotein(a) Particles (KRAKEN)
  • Safety and Efficacy of Obicetrapib in Patients With Heterozygous Familial Hypercholesterolemia (BROOKLYN) 

Featured Science

FS.04 | Featured Science: Vascular Outcomes in the Spotlight
8–9:15 a.m. | S100A
Vascular Medicine

  • Geographical Variations of Treatment Disparities Between Black and White Patients With Peripheral Artery Disease Across the United States
  • Anatomically Directed Lower Extremity Gene Therapy for Ulcer Healing: A Double Blind, Randomized, Placebo Controlled Study (Legend 1 Trial)
  • Bempedoic Acid and Limb Outcomes in Statin-Intolerant Patients With Peripheral Artery Disease: New Insights From the CLEAR OUTCOMES Trial
  • Rivaroxaban for 18 Months vs. 6 Months in Cancer Patients With Low-Risk Pulmonary Embolism: ONCO PE Trial

FS.05: Featured Science | Amyloid, Hypertrophic and Danon Cardiomyopathies: Targeted Therapies and Specific Populations

9:45-11 a.m. | S103BC

  • Danon Disease Phase 1 RP-A501 Results: The First Single-Dose Intravenous Gene Therapy With Recombinant Adeno-Associated Virus (AAV9:LAMP2B) for a Monogenic Cardiomyopathy 
  • Mavacamten Treatment in Patients With Obstructive HCM Referred for Septal Reduction Therapy: 128-Week Results From VALOR-HCM Trial
  • Acoramidis Reduces All-Cause Mortality (ACM) and Cardiovascular-Related Hospitalization (CVH): Initial Outcomes From the ATTRibute-CM Open-Label Extension (OLE) Study
  • Impact of Vutrisiran on Markers of Disease Progression in Patients With Transthyretin Amyloidosis With Cardiomyopathy in the HELIOS-B Trial
  • The Prevalence of Transthyretin Cardiac Amyloidosis in Older Black and Hispanic Individuals With Heart Failure: The Screening for Cardiac Amyloidosis With Nuclear Imaging in Minority Populations Study (SCAN-MP)
  • ATTR-Specific Medication in Dual Pathology Aortic Stenosis and Transthyretin Cardiac Amyloidosis

FS.06 | Featured Science: Novel Insights in Cardiovascular Interventional Outcomes
1:30–2:45 p.m. | S100A
Surgery and Anesthesia

  • Semaglutide Improves Cardiovascular Outcomes in Patients With a History of Coronary Artery Bypass Surgery and Overweight or Obesity: The SELECT Trial
  • Five-Year Results From the AMPLATZER Amulet Left Atrial Appendage Occluder Randomized Controlled Trial (Amulet IDE)
  • The Impact of Carbon Monoxide to Determine the In-Hospital Prognosis After Acute Coronary Syndrome (ADDICT-ICCU) 
  • Quantitative Assessment of Mitral Annular Calcification Severity Predicts Outcomes in Severe Aortic Stenosis Patients Undergoing Transcatheter Aortic Valve Replacement

FS.07 | Featured Science: Incretin Modulation: Is a New Standard of Care Emerging?
1:30–2:45 p.m. | S103BC
Heart Failure and Cardiomyopathies

  • Effect of Tirzepatide on Cardiac Structure and Function in Obese HFpEF: the SUMMIT CMR Substudy
  • Effects of Tirzepatide on the Clinical and Symptom Burden of Patients With Heart Failure and a Preserved Ejection Fraction: Results From the SUMMIT Trial
  • Benefits of Semaglutide on Chronic Kidney Disease Outcomes by Cardiovascular Status or Risk in the FLOW trial 

For more information about these and other #AHA24 sessions, refer to the Online Program Planner.

Meet the Trialist

MTT.04 | Meet the Trialist: MHYH-RCT
Monday, Nov. 18 | 8–8:30 a.m. | Overflow Theater 1, North Building Level 2, McCormick Place Convention Center
Cross Specialty

MTT.05 | Meet the Trialist: ZODIAC
Monday, Nov. 18 | 8:45–9:15 a.m. | Overflow Theater 1, North Building Level 2, McCormick Place Convention Center
Cross Specialty

Interesting Stories
Unmet Needs in Hypertension Toolkit
Sponsored by Medtronic
Unmet Needs in Hypertension Toolkit
CME Gameshow Style Sympo: Navigating New Paradigms in Thrombosis Management
Sponsored by Medscape
CME Gameshow Style Sympo: Navigating New Paradigms in Thrombosis Management
Lp(a) and Peripheral Artery Disease Toolkit
Sponsored by Kaneka Corporation
Lp(a) and Peripheral Artery Disease Toolkit
Screening for Kidney Disease to Reduce CVD Risk
Sponsored by Bayer
Screening for Kidney Disease to Reduce CVD Risk
More Content
Health Tech winners
AHA24
AI medical company wins global health tech competition at #AHA24
Nov 20th, 2024
241116 American Heart Association Keynote 0080
AHA24
LBS 08: Advances in lipid therapeutics
Nov 20th, 2024
Crowd shot
AHA24
LBS 07: New approaches to managing AFib
Nov 20th, 2024
Stage shot
AHA24
LBS 06: Medical therapy for heart failure
Nov 20th, 2024
Stage shot
AHA24
LBS 05: Innovation in prevention
Nov 20th, 2024
Asgar headshot
AHA24
Managing patients with symptomatic mitral or tricuspid regurgitation
Nov 18th, 2024
Shot of speakers
AHA24
Environmental crises call for more CV research
Nov 18th, 2024
Aha24 Nejm Web Image
AHA24
Streamlining the pathway to publish cardiovascular research
Nov 18th, 2024
Casadei headshot
AHA24
Dissecting the complex relationship between atrial cardiomyopathy and stroke
Nov 18th, 2024
Stage shot
AHA24
LBS 04: Coronary and valvular heart disease
Nov 18th, 2024
Stage shot
AHA24
LBS 03: Harnessing AI for better heart health
Nov 18th, 2024
Headshots of speakers
AHA24
Improving patient outcomes for sudden cardiac arrest
Nov 18th, 2024